Dental Practice M&A Glossary

The terms that decide what you keep when you sell — defined in plain English. The standard vocabulary every buyer uses, and the forensic concepts Precision Dental Analytics uses to defend enterprise value before due diligence does the opposite.

Valuation & Multiples

Normalized EBITDA
Earnings before interest, taxes, depreciation, and amortization, adjusted to reflect the practice's economics under new ownership — most importantly, resetting owner-dentist compensation to a fair-market associate rate. It is the number a buyer multiplies to set enterprise value. Learn more →
Seller's Discretionary Earnings (SDE)
EBITDA plus the owner's full compensation — the total economic benefit to a single owner-operator. Individual buyers value smaller practices on SDE (roughly 1.8–3×); institutional buyers use normalized EBITDA. Learn more →
EBITDA Multiple
The figure a buyer multiplies normalized EBITDA by to reach enterprise value. In dental M&A it runs roughly 5–7× under $1M of EBITDA, 7–9× at $1–3M, 9–11× at $3–5M, and 11×+ above $5M (FOCUS Investment Banking, 2026). Learn more →
Enterprise Value
The total value of the practice as a business — Adjusted EBITDA times the applicable multiple — before deal structure (holdback, earnout, rollover) determines how much of it you actually receive at close. Learn more →
Platform vs. Add-On
A platform is a scaled group (generally $3–5M+ of EBITDA) that anchors an investor's strategy and earns the highest multiples; an add-on is a smaller practice tucked into an existing platform at a lower multiple. The spread between the two is typically 3–5×. Learn more →
Personal vs. Enterprise Goodwill
Enterprise goodwill belongs to the business — location, brand, systems, recall engine — and transfers when you sell. Personal goodwill belongs to the dentist — reputation, relationships — and walks out the door with you. Buyers pay full value only for the goodwill that transfers. Learn more →
Key-Person Discount
A reduction in value for a business overly dependent on one individual — roughly 5–25% in the valuation literature, though sophisticated buyers increasingly move owner-dependency risk into earnouts and holdbacks rather than a flat discount. Learn more →
The 15% Floor
The normalized EBITDA margin below which institutional buyers (DSOs and private-equity platforms) generally will not bid, as reported by sell-side M&A advisors. A practice under 15% is not priced at a lower multiple; it is priced in a different market, the individual-buyer market, on Seller's Discretionary Earnings or a percentage of collections. Between 15% and roughly 25% buyers blend methodologies and compress the offer; at or above 25% the practice is underwritten on EBITDA alone. The floor is applied to the normalized margin, after owner compensation, related-party rent, and add-backs are reset, which is why a practice reporting 20% can find itself under the floor once the buyer's Quality of Earnings is finished. Precision Dental Analytics' valuation calculator switches from a pure EBITDA method to a blended method at the same threshold. Learn more →

The Deal

Quality of Earnings (QoE)
A forensic analysis a buyer commissions to validate that reported EBITDA is real and sustainable. It re-examines revenue, add-backs, and clinical-coding compliance — and it is where most post-LOI price reductions originate. Learn more →
SBA Quality of Earnings (SOP 50 10 8.1)
The independent Quality of Earnings report the SBA requires, from October 1, 2026, on 7(a) Initial Acquisition and Business Expansion loans with a business purchase price of $3 million or more (measured before buyer equity or seller financing, excluding owner-occupied real estate; owner buyouts, ESOPs, and cooperatives exempt). It must be prepared by an independent, experienced financial professional for the lender's benefit, never by or for the borrower or seller, and must include a cash proof tying bank statements to the income statement and tax returns for the trailing twelve months and two fiscal years, documentation of every add-back and related-party adjustment, and a revenue-durability assessment. The lender sizes debt service on the QoE earnings (1.25× DSCR on an initial acquisition). For a dental practice it validates that the money moved; the clinical layer, coding patterns, internal codes, credit balances, diagnostic dependency, is a separate read. Learn more →
Add-Back
An expense added back to profit to normalize EBITDA — owner compensation above market, one-time costs, personal expenses run through the practice. 'Hard' add-backs are documented and provable; 'soft' add-backs are subjective, and the first thing a QoE team challenges. Learn more →
Letter of Intent (LOI)
A mostly non-binding document stating the buyer's proposed price and structure, granting them an exclusive 60–120 day window to complete due diligence. The critical point: the LOI price is not the final price. Learn more →
Holdback (Escrow)
A portion of the purchase price the buyer keeps in escrow after closing as recourse if the financials do not hold — commonly 15–20% of price for 24–36 months in dental deals (broader M&A medians run nearer 10–12%). Learn more →
Earnout
Part of the price paid only if the practice hits revenue or EBITDA targets after the sale, typically over 2–3 years. Buyers use earnouts to shift owner-dependency risk onto the seller: the more the practice depends on you, the more of the price moves into the earnout. Learn more →
Rollover Equity
Proceeds the seller reinvests into the buyer's parent company — commonly 20–40% — instead of taking as cash. Marketed as the 'second bite of the apple,' it can be monetized at a higher multiple at the next recapitalization, but it is a minority, illiquid security whose value depends on unit class, waterfall position, dilution, information rights, and exit rights. Learn more →
Pari Passu
Latin for 'on equal footing.' In a rollover equity agreement, pari passu treatment means that when money comes out at exit, the seller's units and the sponsor's units are paid at the same time, at the same rate, from the same pool — nobody ahead in line. Without it, a seller's common units may sit beneath a preferred class whose liquidation preference and accrued return are paid first. Learn more →
Working Capital Adjustment (True-Up)
A post-close reconciliation of net working capital against a negotiated target (the 'peg'); if delivered working capital falls short, the price is reduced dollar-for-dollar. One of the most reliable post-close extraction levers. Learn more →
Re-Trade
A buyer's reduction of the agreed price during due diligence, after the LOI has locked the seller into exclusivity. Across lower-middle-market deals, 85% see a post-LOI price adjustment (SRS Acquiom, 2025) — almost always downward. Learn more →

PDA Forensic Concepts

Phantom EBITDA PDA
A concept coined by Precision Dental Analytics: profit that appears real on the P&L but will not survive institutional due diligence — from non-compliant clinical coding, understated owner compensation, undocumented add-backs, or related-party subsidies (below-market rent to the seller's own real estate entity, supplies from a seller-owned company at no margin). The largest related-party subsidy in most owner-operated practices is the owner: below-market compensation and production a replacement would cost far more to deliver. Phantom EBITDA has three faces, each found by a different reader on the buyer's side: the accounting face (normalization, found by the financial QoE; cuts the price), the operational face (durability, found by the buyer's operators; rewrites the terms), and the clinical face (defensibility, found by clinical diligence or later by the payer; survives close as a liability). Every dollar of Phantom EBITDA is multiplied against the multiple when a buyer removes it. Learn more →
EBITDA Laundering PDA
A PDA-coined term for profit generated through aggressive or non-compliant clinical coding that passes financial underwriting undetected — because transaction accountants overlook the clinical origin of the revenue itself. Learn more →
The Defense Gap PDA
The diligence asymmetry at the heart of most lost value: a buyer spends $50,000–$200,000 or more dissecting your practice, while the average seller spends $0 defending it. Closing that gap before the LOI is the highest-leverage move a seller can make. Learn more →
The 90-Day Extraction PDA
PDA's name for the post-LOI window in which a buyer systematically re-prices the deal — the QoE re-trade, the working-capital peg, the escrow holdback — turning a headline offer into a materially smaller wire between the handshake and the close. Learn more →
Governance Debt PDA
A PDA framework for the accumulated, undocumented liabilities across four domains — financial, provider, operational, and compliance — that a buyer's diligence converts into price reductions. The longer it compounds, the larger the extraction. Learn more →
Clinical Quality of Earnings (CQoE) PDA
A PDA concept: a forensic, pre-emptive audit of a practice's clinical data — the CDT-code-level layer a standard financial QoE misses — run by the seller before the LOI to find and remediate Phantom EBITDA first. Learn more →
Pre-LOI Forensic Sanitization PDA
Running the buyer's exact audit on your own practice, 12–24 months before the letter of intent, so you give yourself the haircut a buyer would — on your terms, with time to fix it — rather than conceding it at the closing table. Learn more →
The Five-Year Asymmetry PDA
A PDA-coined term for the gap between the history sellers prepare and the history buyers audit: sellers clean up 12–18 months of financial statements, while institutional buyers run a 3-year P&L analysis and a 5-year practice-management-software audit. The PMS window covers the years before preparation began — which is why institutional exit preparation takes 3–5 years and cannot be compressed. Learn more →
Toxic Top-Line PDA
A PDA-coined term for revenue that is real — produced, billed, and collected — but not defensible under institutional scrutiny. It inflates EBITDA today, gets stripped in diligence when clinical analytics flag the code-level pattern behind it, and invites retroactive payer clawback. The distinction that decides a sale price is not real versus fake revenue; it is defensible versus indefensible revenue. Learn more →
The Blind Claim PDA
A PDA-coined term for an EBITDA number presented to buyers that the seller has never audited the way the buyer will. The seller's P&L is a claim; the buyer's diligence is the audit. A blind claim shrinks in a spreadsheet the seller never sees — through the Clinical Scrub, key-person findings, and undocumented growth — and every dollar removed is multiplied against the deal multiple. Learn more →
The Clinical Scrub PDA
A PDA-coined term for the forensic extraction of a practice's clinical and ledger data that runs alongside the financial Quality of Earnings review. Dental payers' payment-integrity teams do not screen modifiers or diagnosis codes — CDT claims carry neither — they screen ratios, so the Scrub tests the ratios first: buildup frequency against crowns (D2950 to D2740), SRP and periodontal maintenance as a share of hygiene visits, radiograph frequency, quadrant and same-day patterns by provider, and adjunctive attachment rates. It then reconciles production to claims — the dollars booked under practice-created, non-billable codes that never entered the claims process — and reads the ledger underneath the collection rate: insurance collections above 100% of net production, unapplied insurance credits, patient credit aging, refund patterns, and written-down bad debt. None of it appears on any single default PMS report, and none of it moves the clean-claim rate, denial rate, or AR aging — which is why a practice can pass every revenue-cycle screen and fail the Scrub, and why the first Clinical Scrub most practices ever receive is the buyer's. Learn more →
The Clinical Ledger PDA
A term coined by Joe DeLuca of Precision Dental Analytics for the source-traceable reconstruction of the clinical and operational events that create or destroy practice value — appointments and outcomes, treatment plans, procedures, providers, clinical notes, claims, AR, and marketing-source data, standardized so every metric retains its denominator and source rows. The financial ledger records the result; the Clinical Ledger reconstructs the system that produced it and whether it transfers without the owner. Learn more →
The Decay Constant PDA
A term coined by Joe DeLuca of Precision Dental Analytics (September 2026) for the rate at which a practice protects, or gives away, its next clinically appropriate continuing-care opportunity before the patient leaves the building. Measured as same-day appropriate reappointment: of the patients who completed an eligible hygiene or periodontal-maintenance visit, the share who left with the next right visit on the schedule, read against the clinical pathway rather than a generic six-month recall or the insurance frequency. PDA's operating standard is 90%; the average across practices PDA evaluates is about 78%. Standard continuing-care reports cannot distinguish a patient booked at checkout from one recovered by outreach weeks later, so the Clinical Ledger follows the patient journey instead: eligible visit completed, pathway identified, same-day scheduling path, pipeline status, exception activity, continuing-care status. It is a ratio, not a production metric, and in diligence it reads as durability: whether next year's hygiene base is already on the schedule without the owner chasing it. Learn more →
The Point Guard PDA
A PDA-coined term for the provider — usually the owner — who originates a disproportionate share of a practice's diagnosed treatment without producing a proportionate share of its revenue: 4.4% of exams and 4.8% of production, but 24.6% of everything proposed, in the exemplar. He doesn't score; he distributes. Remove him and the comprehensive pipeline is not handed to someone else — it stops being diagnosed. Learn more →
Diagnostic Dependency PDA
A PDA-coined distinction from production dependency. Production dependency asks who does the work; diagnostic dependency asks who decides what work gets proposed — the share of diagnosed treatment originating from one provider. It lives in the treatment-plan provider field of the practice management software, not the ledger, which is why revenue-by-provider analysis in a financial QoE never sees it. Measured with the assist matrix: treatment planned by one provider, completed by another. Learn more →
The Completion Gap PDA
A term coined by Joe DeLuca of Precision Dental Analytics: the distance between treatment a patient accepted and treatment actually completed within a defined clinical time window, with the reason for any change, delay, phase, or abandonment documented. Case acceptance is a decision at a moment in time; treatment-plan completion is the proof the practice converted a diagnosis into completed care. Buyers purchase a record of completed care, not an inventory of accepted plans. Learn more →
The Owner's Shadow PDA
A term coined by Joe DeLuca of Precision Dental Analytics (October 2026) for the gap between the systems a practice says it has and the decisions the team cannot make without the owner stepping in. It rarely looks like a doctor refusing to delegate; it looks like a good owner being available, until the team learns that the safest way to handle any uncertainty is to route it back to the owner. A practice can hold SOPs, a strong culture, and experienced people and still operate from the owner's availability rather than its systems. Documented systems without decision rights, escalation points, and coaching do not create transferability; they create instructions that still need the seller to interpret them. For many established practices, shrinking the Shadow takes 12 to 24 months of behavior change, which is why a buyer tests whether the team uses the SOPs, not whether the binder exists. Learn more →
The Preparation Gap PDA
A term coined by Joe DeLuca of Precision Dental Analytics (October 2026) for the distance between the two years of operating history a buyer will examine and the three to five years an owner needs to build durable proof. The buyer's lookback is an evidence window, not the seller's starting line: operational changes take 12 to 24 months to become durable behavior, and the evidence then needs time to age before a buyer will price it as proof rather than potential. The Gap is not closed with a better broker deck or by arguing with a Quality of Earnings report after the finding; it is closed before the process begins, by establishing an operating baseline from the Clinical Ledger, changing the behavior behind the number, and letting the record mature inside the buyer's window. The companion to the Five-Year Asymmetry: that term describes the history buyers audit, this one the runway sellers need. Learn more →

Know the Terms. Then Know Your Number.

See what your practice is worth on the same EBITDA-and-multiple basis a buyer will use.